Facts & figures
As of: January, 2019
1) primarily from public funds (EU, Federal Government, State Government); according to Campus Buch: total funding since 1992, incl. BIMSB
2) primarily from own ressources, since 2001
3) primarily from own ressources
4) since 2009
5) since 2006
6) since 2002
Research Institutions of Campus Berlin-Buch Employees (total) |
2,151 |
|
of these: | ||
Max Delbrück Center for Molecular Medicine (MDC): | 1,646 | |
Leibniz Institute of Molecular Pharmacology (FMP): | 303 | |
Klinische Forschung Charité Campus Buch: | 202 | |
Budget and third-party grants (total)1 | EUR 192 million | |
Max Delbrück Center for Molecular Medicine (MDC): | EUR 147 million | |
Leibniz Institute of Molecular Pharmacology (FMP): | EUR 29 million | |
Klinische Forschung Charité Campus Buch: | EUR 16 million | |
BiotechPark Berlin-Buch | ||
Number of companies: | 62 | |
Employees: | 800 | |
Annual revenue: Percentage of third-party grants: 3,1% |
EUR 220 million |
|
Hospitals & Patient-Care Institutions | ||
Employees (total): of these: |
3,564 | |
HELIOS Klinikum Berlin-Buch: | 2,700 | |
Evangelische Lungenklinik: | 325 | |
Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik): | 89 |
|
Patient-care institutions: | 450 | |
Number of patient beds: | 1,267 | |
Patients per year (inpatient and outpatient): | 220,519 | |
Total investment volume of these: |
EUR 1.451 billion | |
Infrastructure Campus Berlin-Buch1 | EUR 624 million | |
HELIOS Klinikum Berlin-Buch² | EUR 336 million | |
Evangelische Lungenklinik3 | EUR 49 million | |
Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik)1 | EUR 39 million |
|
LudwigPark 3 | EUR 45 million | |
Allées des Châteaux 3 | EUR 23 million | |
Widerker Vermögensverwaltung (Schlosspark-Passage) 3 | EUR 29 million |
|
Ludwig Hoffmann Quartier | EUR 152 million |
|
Housing construction associations (HOWOGE 3,4, EWG 3,5, WBG 3,6 Hau+S 3,5 ) | EUR 154 million |
News Buch Berlin
Starting up with highly promising immunotherapies
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse...
more ...OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease
OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, today provided a positiv...
more ...The thrill of science
Young students are fascinated by the experiments they can participate in at the Gläsernes Labor (Life Science Learning Lab). Thanks to a special fundraiser, socially disadvantaged children from the di...
more ...Events Buch Berlin
09.10.2023, 09:00
Explore Precision Medicine Event im Futurium
Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.
more ...